natgillin/translations-raw huggingface dataset:
vanilla flavour (containing p-hydroxybenzoic acid, p-hydroxybenzaldehyde, vanillic acid, vanillin, heliotropin, ethyl vanillin), polyoxyl 40 hydrogenated castor oil, cotton candy flavour (containing ethyl maltol, ethyl vanillin, acetoin, dihydrocoumarin, propylene glycol), acesulfame potassium, saccharin sodium, sodium chloride, peppermint oil, sodium citrate, citric acid, levomenthol.
dihidrokumarin, propilenglikol), kalijev acesulfamat, natrijev saharinat, natrijev klorid, eterično olje poprove mete, natrijev citrat, citronska kislina, levomentol.
Oral solution contains: alcohol (42.4% v/v), high fructose corn syrup, propylene glycol (15.3% w/v), purified water, glycerol, povidone, magnasweet-110 flavour (mixture of monoammonium glycyrrhizinate and glycerol),
Peroralna raztopina vsebuje: alkohol (42,4 % v/v) visokofruktozni koruzni sirup propilenglikol (15,3 % m/v)
Important to open
Nujno odlepite.
Concentrations may be affected when co-administered with lopinavir/ritonavir due to CYP2C9 induction.
zaradi večjih plazemskih koncentracij, ki jih povzroči lopinavir/ritonavir z zavrtjem CYP3A4.
Sildenafil used to treat erectile dysfunction may be taken under doctor's supervision
Za zdravljenje erektilne disfunkcije lahko sildenafil uporabljate pod zdravniškim nadzorom (glejte poglavje Druga zdravila in zdravilo Kaletra).
Refer to the afatinib SmPC for dosage adjustment recommendations.
Za priporočila glede prilagoditve odmerjanja glejte povzetek glavnih značilnosti zdravila za afatinib.
Paediatric dosing guidelines for the dose 230/57.5 mg/m2 > 6 months to < 18 years
Shemi 230/57,5 mg/m2
Copovidone
Bupropion
Outcomes at Week 48: Study M98-957
Rezultati v 48. tednu: Študija M98-957 Kaletra 400/100 mg (N=57)
• medicines affecting the immune system (e.g. cyclosporin, sirolimus (rapamycin), tacrolimus);
(npr. bosentan, riociguat, sildenafil, tadalafil); - zdravila z vplivom na imunski sistem (npr. ciklosporin, sirolimus (rapamicin), takrolimus); - zdravila, ki se uporabljajo za odvajanje od kajenja (npr. bupropion);
Hazard ratio for death or failure of therapy* * Failure defined as clinical, immunological disease progression, virological failure or regimen limiting ART toxicity p=0.0005 (40 week arm); p< 0.0008 (96 week arm)
p=0.0005 (skupina s 40-tedenskim zdravljenjem); p< 0.0008 (skupina s 96-tedenskim zdravljenjem)
BSA (m2) = √ (Height (cm) X Weight (kg) / 3600) It is recommended that Kaletra not be administered in combination with efavirenz or nevirapine in patients less than 6 months of age.
telesna površina (m2) = √ (višina (cm) X telesna masa (kg) / 3600) Otroci do 2. leta starosti
Concentrations may be reduced due to induction of CYP3A by the herbal preparation St John's wort.
Lopinavir: zaradi indukcije CYP3A z zeliščnim pripravkom šentjanževko se koncentracija lahko zniža.
Collar
Konica
Carbamazepine and phenobarbital levels should be monitored when co-administering with Kaletra.
Kaletra, je treba kontrolirati koncentracijo karbamazepina oz. fenitoina.
An increase in weight and in levels of blood lipids and glucose may occur during antiretroviral therapy.
Med protiretrovirusnim zdravljenjem se lahko poveča telesna masa ter zviša koncentracija lipidov in glukoze v krvi.
• protease inhibitors (e.g. fosamprenavir, indinavir, ritonavir, saquinavir, tipranavir);
- peroralni kontraceptivi ali kontraceptivi v obližu za preprečevanje nosečnosti (glejte poglavje spodaj z naslovom “Kontraceptivi”); - zaviralci proteaz (npr. fosamprenavir, indinavir, ritonavir, sakvinavir, tipranavir); - pomirjevalna zdravila (npr. injicirani midazolam); - steroidi (npr. budezonid, deksametazon, flutikazonpropionat, etinilestradiol, triamcinolon);
For the treatment of pulmonary arterial hypertension:
- zdravila za zdravljenje pljučne arterijske hipertenzije (visokega krvnega tlaka v pljučni arteriji)
The use of rivaroxaban is not recommended in patients receiving concomitant treatment with Kaletra (see section 4.4).
Uporaba rivaroksabana ni priporočljiva pri bolnikih, ki sočasno prejemajo zdravilo
7.5 mg/ml Solution for injection
Abilify 7,5 mg/ ml raztopina za injiciranje intramuskularn a uporaba steklena viala
Intramuscular use vial (glass)
ime jakost farmacevtska oblika pot uporabe ovojnina vsebina velikost pakiranja peroralna pretisni omot
Outcome of a procedure under Article 6(12) of Regulation (EC) 1084/2003 as amended
Izid postopka po členu 6(12) Uredbe (ES) 1084/2003, kakor je bila spremenjena
This variation was to be recognised in Austria, Belgium, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, the Netherlands, Portugal, Spain, Sweden and the United Kingdom
Ta sprememba bi se morala priznati: v Avstriji, Belgiji, na Finskem, v Franciji, Grčiji, na Irskem, v Italiji, Luksemburgu, Nemčiji, na
The Committee looked at the studies presented by the company to support the new indication.
Odbor je pregledal predložene študije družbe v podporo novi indikaciji.
The European Commission issued a decision on 02 September 2010.
Evropska komisija je odločbo izdala dne 02. septembra 2010.
Rapporteur:
Poročevalka:
Another point was the fact that the company had presented too few data on the final height reached by the patients in the studies.
Pomembno je bilo tudi dejstvo, da je družba predstavila premalo podatkov o končni višini, ki so jo dosegli bolniki v študijah.
Because the Member States were not able to reach an agreement, the Netherlands referred the matter to the CHMP for arbitration on 28 October 2009.
Vendar se države članice niso uspele dogovoriti in Nizozemska je dne 28. oktobra 2009 zadevo napotila na CHMP v arbitražo.
Why was Genotropin reviewed?
Zakaj je bilo zdravilo Genotropin pregledano?
1 In all other Member States of the EU, the medicine has received a marketing authorisation at national level.
1 V vseh ostalih državah članicah EU je bilo za zdravilo izdano dovoljenje za promet na nacionalni ravni.
The company that makes the medicine is Pfizer.
Družba, ki izdeluje zdravilo, je Pfizer.
In 15 Member States of the EU, Genotropin is authorised under a mutual recognition procedure on the basis of the initial authorisation granted by Denmark on 7 May 19871.
Zdravilo Genotropin je odobreno v 15 državah članicah EU s postopkom z medsebojnim priznavanjem na podlagi prvotnega dovoljenja za promet, ki je bilo odobreno na Danskem dne 7. maja 19871.
25 January 2010, 3 May 2010 and 24 May 2010
25. januar 2010, 3. maj 2010 in 24. maj 2010
The European Medicines Agency has completed an arbitration procedure for Genotropin and associated names.
Evropska agencija za zdravila je zaključila arbitražni postopek za zdravilo Genotropin in povezana imena.
The Committee concluded that the change to the marketing authorisation cannot be granted.
Odbor je sklenil, da spremembe dovoljenja za promet z zdravilom ni mogoče odobriti.
Genotropin, also marketed under the trade name Genotonorm, is available throughout the European Union (EU).
Zdravilo Genotropin se trži tudi z imenom Genotonorm in je na voljo po vsej Evropski Uniji (EU).
In July 2008, Pfizer applied for a change (variation) to the marketing authorisation to add a new indication in Denmark (the ‘reference Member State').
Družba Pfizer je julija 2008 vložila vlogo za spremembo (variacijo) dovoljenja za promet z zdravilom za vključitev nove indikacije na Danskem (v „referenčni državi članici“).
Based on the evaluation of the currently available data and the scientific discussion within the Committee, the CHMP concluded that the variation to the marketing authorisation for Genotropin cannot be approved in Denmark as well as in all concerned Member States.
CHMP je po vrednotenju trenutno razpoložljivih podatkov in znanstveni razpravi v Odboru zaključil, da spremembe dovoljenja za promet z zdravilom Genotropin ni mogoče odobriti na Danskem in tudi ne v zadevnih državah članicah.
What is Genotropin?
Kaj je zdravilo Genotropin?
Genotropin is a medicine that contains somatropin, which is a copy of natural growth hormone.
Genotropin je zdravilo, ki vsebuje somatropin, kopijo naravnega rastnega hormona.
Growth hormone promotes growth during childhood and adolescence, and also acts on the way the body handles proteins, fat and carbohydrates.
Rastni hormon spodbuja rast v času otroštva in adolescence ter vpliva na način, kako telo presnavlja beljakovine, maščobo in ogljikove hidrate.
The grounds for the referral were that fewer patients currently need to use steroids than in the past, because other medicines that do not affect growth have become available to control JIA.
Podlaga za napotitev je temeljila na tem, da je trenutno manj bolnikov, ki morajo za nadzorovanje JIA uporabljati steroide kot v preteklosti, saj so na voljo druga zdravila, ki ne vplivajo na rast.
It also looked at published information on the use of growth hormone in patients with JIA, and convened a meeting of experts, which included experts both in the treatment of hormonal disorders (endocrinologists) and in the treatment of joint diseases (rheumatologists).
Prav tako je proučil objavljene informacije o uporabi rastnega hormona pri bolnikih z JIA ter sklical srečanje strokovnjakov, na katerem so sodelovali strokovnjaki s področja zdravljenja hormonskih motenj (endokrinologi) in zdravljenja bolezni sklepov (revmatologi).
24 June 2010
24. junij 2010
It is also used to correct short height in children who have the genetic diseases Turner syndrome and Prader Willi syndrome, and in children who have longstanding kidney problems.
Uporablja se tudi za uravnavanje nizke rasti pri otrocih z genetskimi obolenji, s Turnerjevim sindromom in Prader Willijevim sindromom ter pri otrocih z dolgotrajnimi težavami z ledvicami.
The Agency's Committee for Medicinal Products for Human Use (CHMP) had been asked to arbitrate on a change to the marketing authorisation for Genotropin to include a new indication for the treatment of stunted growth caused by the long-term use of steroids in children with juvenile idiopathic arthritis.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji so zaprosili, da sprejme odločitev o spremembi dovoljenja za promet z zdravilom Genotropin z vključitvijo nove indikacije za zdravljenje upočasnjene rasti zaradi dolgotrajne uporabe steroidov pri otrocih z juvenilnim idiopatskim artritisom.
Genotropin is used as replacement therapy in children and adults who have a growth hormone deficiency.
Zdravilo Genotropin se uporablja kot nadomestna terapija pri zdravljenju otrok in odraslih s pomanjkanjem rastnega hormona.
These national marketing authorisations are not affected by this referral.
Napotitev ne vpliva na ta dovoljenja za promet z zdravilom.
The new indication was the use of Genotropin in children on long-term treatment with steroids for juvenile idiopathic arthritis (JIA), a rare childhood disease causing inflammation of many joints.
Nova indikacija je bila uporaba zdravila Genotropin pri otrocih, dolgotrajno zdravljenih s steroidi zaradi juvenilnega idiopatskega artritisa (JIA), redke otroške bolezni, ki povzroča vnetje več sklepov.
Genotropin was to be used to improve growth and body composition in children with severe JIA in whom the prolonged use of steroids to help control inflammation had led to a slowing down of growth.
Zdravilo Genotropin naj bi se uporabljalo za izboljšanje rasti in telesne sestave otrok s hudim JIA, pri katerih je dolgotrajna uporaba steroidov za nadzorovanje vnetij upočasnila rast.
Somatropin is produced by a method known as ‘recombinant DNA technology': it is made by an organism that has received a gene (DNA), which makes it able to produce growth hormone.
Izdeluje ga organizem, ki je po prejemu gena (DNK) zmožen proizvajati rastni hormon.
This summary was last updated in 02-2013.
Povzetek je bil nazadnje posodobljen 02-2013.
• Parkinson's disease.
• Parkinsonove bolezni.
The dose can then be increased every week until an effective dose is reached.
Odmerek je mogoče nato povečevati vsak teden, dokler ne dosežemo učinkovitega odmerka.
This medicine is the same as Neupro, which is already authorised in the European Union (EU).
To zdravilo je enako zdravilu Neupro, ki je že odobreno v Evropski uniji (EU).
The European Commission granted a marketing authorisation valid throughout the European Union for Leganto on 16 June 2011.
Evropska komisija je dovoljenje za promet z zdravilom Leganto, veljavno po vsej Evropski uniji, odobrila dne 16. junija 2011.
The same place must not be used again until two weeks later.
V prihodnjih dveh tednih se ne sme namestiti na isto mesto.
The patch remains on the skin for 24 hours and is then replaced by a new one in a different place.
Na koži ostane 24 ur, nato pa se nadomesti z novim obližem na drugem mestu.
Leganto is applied once a day at about the same time every day.
Zdravilo Leganto se namesti enkrat dnevno, vsak dan ob približno istem času.
The full EPAR for Leganto can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Leganto je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
EPAR summary for the public rotigotine
Povzetek EPAR za javnost rotigotin
The patients then lose their ability to control their movements reliably.
Bolniki nato izgubijo sposobnost zanesljivega nadzora nad svojimi gibi.
The strength of patch to use at the start of treatment depends on the type and stage of the disease being treated.
Jakost obliža, ki ga je treba uporabiti na začetku zdravljenja, je odvisna od vrste in stopnje zdravljene bolezni.
Leganto is used when a specific cause for the disorder cannot be identified.
Zdravilo Leganto se uporablja, kadar točnega vzroka motnje ni mogoče ugotoviti.
Each patch releases 1, 2, 3, 4, 6 or 8 mg of the active substance rotigotine over 24 hours.
Vsak obliž sprosti 1, 2, 3, 4, 6 ali 8 mg zdravilne učinkovine rotigotin v obdobju 24 ur.
This is a summary of the European public assessment report (EPAR) for Leganto.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Leganto.
Other information about Leganto
Druge informacije o zdravilu Leganto
Dopamine is a messenger substance in the parts of the brain that control movement and co-ordination.
Dopamin je prenašalec v tistem delu možganov, ki nadzira gibanje in koordinacijo.
Leganto was less effective than ropinirole: an improvement was seen in 70% of the patients receiving ropinirole.
Zdravilo Leganto je bilo manj učinkovito od ropinirola: izboljšanje je bilo opaženo pri 70 % bolnikov, ki so prejemali ropinirol.
The way rotigotine works in restless legs syndrome is not fully understood.
Način delovanja rotigotina pri sindromu nemirnih nog ni povsem znan.
• moderate to severe restless legs syndrome, a disorder where the patient has uncontrollable urges to move the limbs to stop uncomfortable, painful or odd sensations in the body, usually at night.
• zmernega do hudega sindroma nemirnih nog, tj. motnje, pri kateri ima bolnik nenadzorovano potrebo po premikanju okončin, da bi se znebil neprijetnih, bolečih ali nenavadnih občutkov v telesu, običajno ponoči.
What benefit has Leganto shown during the studies?
Kakšne koristi je zdravilo Leganto izkazalo med študijami?
In patients with Parkinson's disease, the cells that produce dopamine begin to die and the amount of dopamine in the brain decreases.
Pri bolnikih s Parkinsonovo boleznijo začnejo celice, ki proizvajajo dopamin, odmirati, zato se količina dopamina v možganih zmanjša.
For more information about treatment with Leganto, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Leganto preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Leganto is used to treat the symptoms of the following diseases in adults:
Zdravilo Leganto se uporablja za zdravljenje odraslih s simptomi naslednjih bolezni:
Rotigotine then stimulates the brain as dopamine would, so that patients can control their movement and have fewer of the signs and symptoms of Parkinson's disease, such as stiffness and slowness of movement.
Rotigotin zatem stimulira možgane enako kot dopamin, tako da lahko bolniki spet nadzirajo svoje gibe in kažejo manj znakov in simptomov Parkinsonove bolezni, kot so togost in počasnost gibov.
The backing layer of Leganto contains aluminium.
Vrhnja plast obliža Leganto vsebuje aluminij.
Leganto was more effective than placebo in treating Parkinson's disease.
Zdravilo Leganto je bilo pri zdravljenju Parkinsonove bolezni učinkovitejše od placeba.
The main measure of effectiveness was the change in symptoms after six months of treatment with a stable dose, measured using two standard scales.
Glavno merilo učinkovitosti je bila sprememba v simptomih, izmerjena z uporabo dveh standardnih lestvic, po šestih mesecih zdravljenja s stalnim odmerkom.
Leganto must not be used in people who are hypersensitive (allergic) to rotigotine or any of the other ingredients.
Zdravila Leganto ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) rotigotin ali katero koli drugo sestavino zdravila.
The studies in advanced disease measured the length of time during the day that the patients recorded as ‘off' (when they had too many Parkinson's disease symptoms to be able to live normally).
V študijah napredovale bolezni so merili trajanje obdobja v dnevu, ki so ga bolniki označili kot „izklop“ (ko so imeli preveč simptomov Parkinsonove bolezni naenkrat za normalno življenje).
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Leganto.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Leganto, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
The syndrome is thought to be caused by problems in the way dopamine works in the brain, which may be improved by rotigotine.
Domneva se, da ga povzročajo težave v načinu delovanja dopamina v možganih, kar pa se lahko izboljša z uporabo rotigotina.
The studies in early-stage disease looked at the number of patients who had at least a 20% improvement in symptoms, as measured with a standard symptom questionnaire.
V študijah zgodnje faze bolezni so proučevali število bolnikov, pri katerih je bilo opazno najmanj 20-odstotno izboljšanje simptomov, kar so ugotovili s standardnim vprašalnikom o simptomih.
What is the risk associated with Leganto?
Kakšna tveganja so povezana z zdravilom Leganto?
The active substance in Leganto, rotigotine, is a dopamine agonist, which means that it imitates the action of dopamine.
Zdravilna učinkovina zdravila Leganto, rotigotin, je agonist dopamina, kar pomeni, da posnema delovanje dopamina.
Leganto is used on its own in early-stage disease, or in combination with levodopa (another medicine used in Parkinson's disease) at any stage of the disease, including the later stages when levodopa starts becoming less effective;
Zdravilo Leganto se uporablja kot samostojno zdravilo v zgodnji fazi bolezni ali v kombinaciji z levodopo (drugim zdravilom za zdravljenje Parkinsonove bolezni) v kateri koli fazi bolezni, vključno v poznih fazah, ko začne učinek levodope popuščati;
The company that makes Neupro has agreed that its scientific data can be used for Leganto (‘informed consent').
Družba, ki izdeluje zdravilo Neupro, se strinja, da se lahko znanstveni podatki o tem zdravilu uporabijo tudi za zdravilo Leganto („uporaba dokumentacije s soglasjem“).
In early-stage disease, 48 to 52% of the patients using Leganto had an improvement in symptoms, compared with 19 to 30% of those using placebo.
V zgodnji fazi bolezni je pri 48 do 52 % bolnikov, ki so jemali zdravilo Leganto, prišlo do izboljšanja simptomov v primerjavi z 19 do 30 % tistih, ki so jemali placebo.
Leganto is a range of transdermal patches (patches that deliver a medicine across the skin).
Zdravilo Leganto je serija transdermalnih obližev (ki dovajajo zdravilo skozi kožo).
The patch is applied to dry, clean, healthy skin on the abdomen (tummy), thigh, hip, side, shoulder or upper arm.
Obliž se namesti na suho, čisto, zdravo kožo na trebuhu, stegnu, kolku, boku, ramenu ali nadlakti.
Two of these studies also compared Leganto with other dopamine agonists (ropinirole in early-stage disease and pramipexole in advanced disease).
V dveh od teh študij so zdravilo Leganto primerjali tudi z drugimi agonisti dopamina (ropinirolom v zgodnji fazi bolezni in pramipeksolom pri napredovali bolezni).
In moderate to severe restless legs syndrome, Leganto has been compared with placebo in two main studies involving a total of 963 patients.
Pri zmernem do hudem sindromu nemirnih nog so zdravilo Leganto primerjali s placebom v dveh glavnih študijah, v katerih je sodelovalo skupaj 963 bolnikov.
The most common side effects with Leganto in patients with Parkinson's disease (seen in more than 1 patient in 10) are somnolence (sleepiness), dizziness, headache, nausea (feeling sick), vomiting, and application site reactions such as redness, itching and irritation of the skin.
Najpogostejši neželeni učinki zdravila Leganto pri bolnikih s Parkinsonovo boleznijo (opaženi pri več kot 1 bolniku od 10) so zaspanost, omotica, glavobol, navzeja (slabost), bruhanje in reakcije na mestu nanosa, npr. pordelost, srbečica in vzdraženost kože.
In smaller studies completed later, the effectiveness of Leganto was found to be comparable with ropinirole.
V manjših študijah, izvedenih naknadno, je bila učinkovitost zdravila Leganto primerljiva z ropinirolom.
In Parkinson's disease, Leganto has been compared with placebo (a dummy treatment) in four studies involving 830 patients with early-stage disease and 842 patients with advanced disease.
Pri zdravljenju Parkinsonove bolezni so zdravilo Leganto primerjali s placebom (zdravilom brez zdravilne učinkovine) v štirih študijah, v katerih je sodelovalo 830 bolnikov v zgodnjem stadiju bolezni in 842 bolnikov z napredovalo boleznijo.
The CHMP decided that Leganto's benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Leganto večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
For the full list of all side effects reported with Leganto, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Leganto, glejte navodilo za uporabo.
Why has Leganto been approved?
Zakaj je bilo zdravilo Leganto odobreno?
The maximum dose is 8 mg/24 h for early-stage Parkinson's disease and 16 mg/24 h for advanced disease.
V zgodnji fazi Parkinsonove bolezni je najvišji odmerek 8 mg/24 h, pri napredovali bolezni pa 16 mg/24 h. Pri sindromu nemirnih nog znaša največji odmerek 3 mg/24 h.
To avoid skin burns, Leganto must be removed if the patient has to have magnetic resonance imaging (MRI) or cardioversion (a process that restores the heart's normal rhythm).
Če je treba pri bolniku opraviti magnetnoresonančno slikanje (MRI) ali kardioverzijo (postopek za ponovno vzpostavitev normalnega srčnega ritma), je treba obliž Leganto odstraniti, da se preprečijo opekline kože.
In advanced Parkinson's disease, patients using Leganto had a greater decrease in their ‘off' time than those taking placebo (a decrease of 2.1 to 2.7 h with Leganto compared with 0.9 h with placebo).
Pri napredovali Parkinsonovi bolezni se je pri bolnikih, ki so uporabljali zdravilo Leganto, obdobje „izklopa“ skrajšalo bolj (zmanjšanje za 2,1 do 2,7 ure pri uporabi zdravila Leganto v primerjavi s zmanjšanjem za 0,9 ure pri uporabi placeba).
In patients with restless legs syndrome, the most common side effects (seen in more than 1 patient in 10) are nausea, application site reactions, asthenic conditions (conditions such as tiredness, weakness and feeling unwell) and headache.
Pri bolnikih s sindromom nemirnih nog so najpogostejši neželeni učinki (opaženi pri več kot 1 bolniku od 10) slabost, reakcije na mestu nanosa, astenična stanja (stanja, kot so utrujenost, šibkost in občutek nelagodja) ter glavobol.